LifeMD (LFMD) Proxy filing summary

Executive summary

• Achieved record growth in 2025, supporting over 322,000 active patients and completing 1.5 million virtual consults across all 50 states.

• Telehealth revenue increased from $158M in 2024 to $194M in 2025, with a projected $250M run rate by end of 2026 and a five-year CAGR of 45%.

• Strategic collaborations with Eli Lilly and Novo Nordisk provide access to brand-name GLP-1 therapies and position the platform for future pharma partnerships.

• Expanded offerings now include comprehensive programs in women's health, men's health, psychiatry, cardiology, and specialty pharmacy.

• Focused on building a durable, high-quality, virtual-first healthcare platform with strong patient retention and satisfaction metrics.

Voting matters and shareholder proposals

• No explicit voting matters or shareholder proposals were detailed in the provided content.

Board of directors and corporate governance

• Welcomed a new Chief Financial Officer, Atul, bringing public company financial rigor and healthcare depth.

• Leadership team includes seasoned operators in pharmacy, clinical operations, technology, marketing, legal, and compliance.